ストックスクリーナーアプリを入手
4.19
3.71%
0.15
Cervomed Inc (CRVO) 最新ニュース
CervoMed (CRVO)’s Q4 results feature advancements in its neflamapimod program for dementia Lewy bodies (DLB) - MSN
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB) - Insider Monkey
CEO Change: Is CervoMed Inc stock overvalued or fairly priced2026 Technicals & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Top 5 Stocks Under $5 That Could Triple - Insider Monkey
CervoMed Posts Investor Presentation Under Regulation FD Disclosure - TipRanks
CRVO: Phase III DLB trial launches this year, leveraging biomarker-driven selection and robust phase II data - TradingView
CervoMed (NASDAQ: CRVO) furnishes updated investor presentation via 8-K - Stock Titan
CervoMed reports Phase 2b trial data for DLB treatment neflamapimod By Investing.com - Investing.com India
CervoMed Presents New Data Reinforcing Positive Effects of Tuvapimod in Dementia with Lewy Bodies Without Alzheimer’s Co-Pathology at AD/PD 2026 Conference - Minichart
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results - TipRanks
[8-K] CervoMed Inc. Reports Material Event | CRVO SEC FilingForm 8-K - Stock Titan
CervoMed (CRVO): Analyst Maintains Buy Rating with $31 Price Tar - GuruFocus
CervoMed (CRVO) Showcases Promising Trial Results for Neflamapim - GuruFocus
CervoMed Inc Announces New Data on Neflamapimod In Dementia With Lewy Bodies - marketscreener.com
CervoMed reports Phase 2b trial data for DLB treatment neflamapimod - Investing.com
CervoMed Inc. unveils new analyses linking better neflamapimod outcomes to reduced Alzheimer co-pathology - Traders Union
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology - The Manila Times
CRVO: Roth Capital Lowers Price Target, Maintains Buy Rating | C - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target to $21.00 | - GuruFocus
Market Trends: Is CervoMed Inc currently under institutional pressureDollar Strength & Smart Money Movement Tracker - baoquankhu1.vn
CervoMed Reports 2025 Results, Advances Neflamapimod Programs - TipRanks
CRVO: Phase 3 DLB trial planned for H2 2026, with cash runway limited to six months - TradingView
CervoMed (CRVO) widens 2025 loss as cash runway falls to six months - Stock Titan
Aug Macro: Is CervoMed Inc stock overvalued or fairly pricedWeekly Trading Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
H.C. Wainwright reiterates CervoMed stock rating on conference data By Investing.com - Investing.com India
H.C. Wainwright reiterates CervoMed stock rating on conference data - Investing.com
CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates - TradingView
CervoMed Inc. Reports Positive Phase 2b Clinical Data and Plans for Phase 3 Trial in Dementia with Lewy Bodies - Quiver Quantitative
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - ChartMill
CervoMed (CRVO) Planning Major Developments in 2026 - GuruFocus
CervoMed (CRVO) Maintains Current Analyst Ratings and Price Targ - GuruFocus
Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs - The Globe and Mail
CervoMed Inc. (CRVO) reports Q4 loss, lags revenue estimates - MSN
CervoMed Inc. (CRVO) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
CervoMed Inc. Annual Report 2025: Strategy, Key Terms, and Forward-Looking Statements for Age-Related Brain Disorders - Minichart
CervoMed 10-K: $4.01M Grant Revenue; Net Loss $26.97M, $(2.98) EPS - TradingView
CRVO: Neflamapimod achieved robust, durable efficacy in DLB without AD co-pathology, advancing to Phase 3 - TradingView
CRVO: Net loss widened to $27.0 million in 2025; ongoing operations depend on new capital - TradingView
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CervoMed Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference - Sahm
CervoMed (CRVO) to Showcase Neflamapimod Advancements at AD/PD 2 - GuruFocus
CervoMed Announces Presentations at Upcoming AD/PD 2026 Scientific Conference - Bitget
CervoMed Inc neflamapimod selected by UK platform for ALS treatment assessment - Traders Union
Is CervoMed Inc. stock a good choice for value investorsWeekly Gains Report & Short-Term Trading Opportunity Alerts - Naître et grandir
CervoMed to Participate in Upcoming Investor Conferences - Sahm
Analysts Are Bullish on These Healthcare Stocks: Senseonics Holdings (SENS), OmniAb (OABI) - The Globe and Mail
D. Boral Capital Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - Defense World
Chardan Capital Maintains Buy Rating for CRVO | CRVO Stock News - GuruFocus
CervoMed sets 50mg dose for phase 3 dementia trial By Investing.com - Investing.com Canada
CervoMed Finalizes Formulation and Dosing Regimen for Phase 3 Trial in Dementia with Lewy Bodies - geneonline.com
CervoMed Advances Neflamapimod With Phase 1 Completion - TipRanks
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):